Application  ||| S:0 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
basic  ||| S:15 E:21 ||| JJ
research  ||| S:21 E:30 ||| NN
to  ||| S:30 E:33 ||| TO
development  ||| S:33 E:45 ||| NN
of  ||| S:45 E:48 ||| IN
diagnostics  ||| S:48 E:60 ||| NNS
and  ||| S:60 E:64 ||| CC
therapeutic  ||| S:64 E:76 ||| JJ
agents  ||| S:76 E:83 ||| NNS
against  ||| S:83 E:91 ||| IN
inflammatory  ||| S:91 E:104 ||| JJ
diseases  ||| S:104 E:113 ||| NNS
Biomarkers  ||| S:113 E:124 ||| NNS
are  ||| S:124 E:128 ||| VBP
generally  ||| S:128 E:138 ||| RB
important  ||| S:138 E:148 ||| JJ
for  ||| S:148 E:152 ||| IN
the  ||| S:152 E:156 ||| DT
treatment  ||| S:156 E:166 ||| NN
of  ||| S:166 E:169 ||| IN
patients  ||| S:169 E:178 ||| NNS
from  ||| S:178 E:183 ||| IN
the  ||| S:183 E:187 ||| DT
points  ||| S:187 E:194 ||| NNS
of  ||| S:194 E:197 ||| IN
diagnosis  ||| S:197 E:207 ||| NN
of  ||| S:207 E:210 ||| IN
disease ||| S:210 E:217 ||| NN
,  ||| S:217 E:219 ||| ,
assessment  ||| S:219 E:230 ||| NN
of  ||| S:230 E:233 ||| IN
cure ||| S:233 E:237 ||| NN
,  ||| S:237 E:239 ||| ,
assessment  ||| S:239 E:250 ||| NN
of  ||| S:250 E:253 ||| IN
prognosis  ||| S:253 E:263 ||| JJ
such  ||| S:263 E:268 ||| JJ
as  ||| S:268 E:271 ||| IN
metastasis  ||| S:271 E:282 ||| NN
or  ||| S:282 E:285 ||| CC
recurrence ||| S:285 E:295 ||| NN
,  ||| S:295 E:297 ||| ,
prevention  ||| S:297 E:308 ||| NN
of  ||| S:308 E:311 ||| IN
disease ||| S:311 E:318 ||| NN
,  ||| S:318 E:320 ||| ,
and  ||| S:320 E:324 ||| CC
prediction  ||| S:324 E:335 ||| NN
of  ||| S:335 E:338 ||| IN
drug  ||| S:338 E:343 ||| NN
efficacy ||| S:343 E:351 ||| NN
.  ||| S:351 E:353 ||| .
Currently  ||| S:353 E:363 ||| RB
it  ||| S:363 E:366 ||| PRP
is  ||| S:366 E:369 ||| VBZ
well  ||| S:369 E:374 ||| RB
accepted  ||| S:374 E:383 ||| VBN
that  ||| S:383 E:388 ||| IN
allergic  ||| S:388 E:397 ||| JJ
diseases  ||| S:397 E:406 ||| NNS
such  ||| S:406 E:411 ||| JJ
as  ||| S:411 E:414 ||| IN
bronchial  ||| S:414 E:424 ||| JJ
asthma  ||| S:424 E:431 ||| NN
and  ||| S:431 E:435 ||| CC
atopic  ||| S:435 E:442 ||| JJ
dermatitis  ||| S:442 E:453 ||| NNS
are  ||| S:453 E:457 ||| VBP
not  ||| S:457 E:461 ||| RB
single  ||| S:461 E:468 ||| JJ
diseases ||| S:468 E:476 ||| NNS
,  ||| S:476 E:478 ||| ,
but  ||| S:478 E:482 ||| CC
syndromes  ||| S:482 E:492 ||| JJ
encompassing  ||| S:492 E:505 ||| JJ
different  ||| S:505 E:515 ||| JJ
diseases  ||| S:515 E:524 ||| NNS
entities ||| S:524 E:532 ||| NNS
.  ||| S:532 E:534 ||| .
Therefore ||| S:534 E:543 ||| RB
,  ||| S:543 E:545 ||| ,
it  ||| S:545 E:548 ||| PRP
is  ||| S:548 E:551 ||| VBZ
important  ||| S:551 E:561 ||| JJ
to  ||| S:561 E:564 ||| TO
cluster  ||| S:564 E:572 ||| VB
allergic  ||| S:572 E:581 ||| JJ
disease  ||| S:581 E:589 ||| NN
patients  ||| S:589 E:598 ||| NNS
to  ||| S:598 E:601 ||| TO
assess  ||| S:601 E:608 ||| VB
prognosis  ||| S:608 E:618 ||| NNS
or  ||| S:618 E:621 ||| CC
the  ||| S:621 E:625 ||| DT
choice  ||| S:625 E:632 ||| NN
of  ||| S:632 E:635 ||| IN
therapeutic  ||| S:635 E:647 ||| JJ
drugs ||| S:647 E:652 ||| NNS
,  ||| S:652 E:654 ||| ,
and  ||| S:654 E:658 ||| CC
useful  ||| S:658 E:665 ||| JJ
biomarkers  ||| S:665 E:676 ||| NNS
are  ||| S:676 E:680 ||| VBP
required  ||| S:680 E:689 ||| VBN
for  ||| S:689 E:693 ||| IN
these  ||| S:693 E:699 ||| DT
purposes ||| S:699 E:707 ||| NNS
.  ||| S:707 E:709 ||| .
Periostin ||| S:709 E:718 ||| NNP
,  ||| S:718 E:720 ||| ,
an  ||| S:720 E:723 ||| DT
extracellular  ||| S:723 E:737 ||| JJ
matrix  ||| S:737 E:744 ||| JJ
protein ||| S:744 E:751 ||| NN
,  ||| S:751 E:753 ||| ,
has  ||| S:753 E:757 ||| VBZ
recently  ||| S:757 E:766 ||| RB
emerged  ||| S:766 E:774 ||| VBN
as  ||| S:774 E:777 ||| IN
a  ||| S:777 E:779 ||| DT
biomarker  ||| S:779 E:789 ||| JJ
useful  ||| S:789 E:796 ||| JJ
for  ||| S:796 E:800 ||| IN
clustering  ||| S:800 E:811 ||| JJ
asthma  ||| S:811 E:818 ||| NN
patients ||| S:818 E:826 ||| NNS
.  ||| S:826 E:828 ||| .
We  ||| S:828 E:831 ||| PRP
further  ||| S:831 E:839 ||| RB
found  ||| S:839 E:845 ||| VBN
that  ||| S:845 E:850 ||| IN
periostin  ||| S:850 E:860 ||| NN
plays  ||| S:860 E:866 ||| VBZ
an  ||| S:866 E:869 ||| DT
important  ||| S:869 E:879 ||| JJ
role  ||| S:879 E:884 ||| NN
in  ||| S:884 E:887 ||| IN
allergic  ||| S:887 E:896 ||| JJ
inflammation  ||| S:896 E:909 ||| NN
and  ||| S:909 E:913 ||| CC
based  ||| S:913 E:919 ||| VBN
on  ||| S:919 E:922 ||| IN
this  ||| S:922 E:927 ||| DT
finding  ||| S:927 E:935 ||| VBG
we  ||| S:935 E:938 ||| PRP
are  ||| S:938 E:942 ||| VBP
now  ||| S:942 E:946 ||| RB
developing  ||| S:946 E:957 ||| VBG
therapeutic  ||| S:957 E:969 ||| JJ
agents  ||| S:969 E:976 ||| NNS
targeting  ||| S:976 E:986 ||| VBG
periostin  ||| S:986 E:996 ||| NN
against  ||| S:996 E:1004 ||| IN
allergic  ||| S:1004 E:1013 ||| JJ
diseases ||| S:1013 E:1021 ||| NNS
.  ||| S:1021 E:1023 ||| .
Since  ||| S:1023 E:1029 ||| IN
periostin  ||| S:1029 E:1039 ||| NN
is  ||| S:1039 E:1042 ||| VBZ
involved  ||| S:1042 E:1051 ||| VBN
in  ||| S:1051 E:1054 ||| IN
the  ||| S:1054 E:1058 ||| DT
pathogenesis  ||| S:1058 E:1071 ||| NN
of  ||| S:1071 E:1074 ||| IN
various  ||| S:1074 E:1082 ||| JJ
inflammatory  ||| S:1082 E:1095 ||| JJ
diseases  ||| S:1095 E:1104 ||| NNS
in  ||| S:1104 E:1107 ||| IN
addition  ||| S:1107 E:1116 ||| NN
to  ||| S:1116 E:1119 ||| TO
allergic  ||| S:1119 E:1128 ||| VB
diseases ||| S:1128 E:1136 ||| NNS
,  ||| S:1136 E:1138 ||| ,
such  ||| S:1138 E:1143 ||| JJ
diagnostics  ||| S:1143 E:1155 ||| NNS
and  ||| S:1155 E:1159 ||| CC
therapeutic  ||| S:1159 E:1171 ||| JJ
agents  ||| S:1171 E:1178 ||| NNS
can  ||| S:1178 E:1182 ||| MD
be  ||| S:1182 E:1185 ||| VB
applied  ||| S:1185 E:1193 ||| VBN
to  ||| S:1193 E:1196 ||| TO
many  ||| S:1196 E:1201 ||| JJ
inflammatory  ||| S:1201 E:1214 ||| JJ
diseases ||| S:1214 E:1222 ||| NNS
.  ||| S:1222 E:1224 ||| .
In  ||| S:1224 E:1227 ||| IN
this  ||| S:1227 E:1232 ||| DT
article ||| S:1232 E:1239 ||| NN
,  ||| S:1239 E:1241 ||| ,
we  ||| S:1241 E:1244 ||| PRP
describe  ||| S:1244 E:1253 ||| VBP
the  ||| S:1253 E:1257 ||| DT
history  ||| S:1257 E:1265 ||| NN
of  ||| S:1265 E:1268 ||| IN
periostin  ||| S:1268 E:1278 ||| JJ
research  ||| S:1278 E:1287 ||| NN
and  ||| S:1287 E:1291 ||| CC
our  ||| S:1291 E:1295 ||| PRP$
application  ||| S:1295 E:1307 ||| NN
of  ||| S:1307 E:1310 ||| IN
basic  ||| S:1310 E:1316 ||| JJ
research  ||| S:1316 E:1325 ||| NN
to  ||| S:1325 E:1328 ||| TO
the  ||| S:1328 E:1332 ||| DT
development  ||| S:1332 E:1344 ||| NN
of  ||| S:1344 E:1347 ||| IN
diagnostics  ||| S:1347 E:1359 ||| NNS
and  ||| S:1359 E:1363 ||| CC
therapeutic  ||| S:1363 E:1375 ||| JJ
agents  ||| S:1375 E:1382 ||| NNS
against  ||| S:1382 E:1390 ||| IN
inflammatory  ||| S:1390 E:1403 ||| JJ
diseases ||| S:1403 E:1411 ||| NNS
.  ||| S:1411 E:1413 ||| .
